ArticleDisease markers2022
Combined Transcriptomic and Metabolomic Analysis of Women with Polycystic Ovary Syndrome.
Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Extracellular vesicles in reproductive biology and disorders: a comprehensive review.Frontiers in endocrinology · 2025Pooled it
- Mechanisms and applications of mesenchymal stem cell exosomes in enhancing fertility.Stem cell research & therapy · 2025Review
- Transcriptomic Profiling Reveals Potential Genes Involved in the Immune Landscape of Polycystic Ovary Syndrome: An Exploratory Study.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Circulating Cell Free microRNAs in Women with Polycystic Ovary Syndrome: Advancing Towards Biomarker Discovery and Therapeutic Targets.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- miR-34a-5p modulation of polycystic ovary syndrome via targeting the NOTCH signaling pathway.Journal of ovarian research · 2025Article
- Time-series metabolomic analysis revealed altered metabolism of cynomolgus monkeys after injecting exosomes.Journal of nanobiotechnology · 2024Article
- Unraveling the pathogenic interplay between SARS-CoV-2 and polycystic ovary syndrome using bioinformatics and experimental validation.Scientific reports · 2024Article
- Identification and validation of senescence-related genes in polycystic ovary syndrome.Journal of ovarian research · 2024Article
- Exosomal circ_0008285 in follicle fluid regulates the lipid metabolism through the miR-4644/ LDLR axis in polycystic ovary syndrome.Journal of ovarian research · 2023Article
- The physiological functions and therapeutic potential of exosomes during the development and treatment of polycystic ovary syndrome.Frontiers in physiology · 2023Review
- Stem cells and exosomes: as biological agents in the diagnosis and treatment of polycystic ovary syndrome (PCOS).Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) is a complex class of endocrine disorders with insulin resistance, compensatory hyperinsulinemia, and obesity. However, the pathogenesis and therapies of PCOS have not been fully elucidated. Exosomal miRNAs have the potential to serve as biomarkers and therapies for a wide range of medical conditions. Method: We collected follicular fluid from 5 PCOS patients and 5 healthy people. High-throughput sequencing technology to identify differentially expressed miRNAs and untargeted metabolome identify differential metabolites in follicular fluid exosomal. RT-qPCR and AUC analysis were performed. Result: miRNA high-throughput sequencing identified 124 differential miRNAs. RT-qPCR analysis confirmed the sequencing results. These differential miRNA target genes are mainly involved in metabolic pathways. Metabolomics studies identified 31 differential metabolites. miRNA and lncRNA coexpression networks in metabolic pathways rigorously screened 28 differentially expressed miRNAs. This network would identify miRNA signatures associated with metabolic processes in PCOS. Meanwhile, the area under curve of receiver operating characteristic revealed that hsa-miR-196a-3p, hsa-miR-143-5p, hsa-miR-106a-3p, hsa-miR-34a-5p, and hsa-miR-20a-5p were potential biomarkers for the diagnosis of PCOS. Conclusion: Collectively, these results demonstrate the potential pathogenesis of PCOS, and follicular fluid exosomal miRNAs may be efficient targets for the diagnosis and treatment of PCOS in long-term clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.